Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

November 19, 2018

FDA approves Novartis drug Promacta for first-line SAA

The US Food and Drug Administration (FDA) has expanded the label for Novartis’ Promacta (eltrombopag) to include first-line treatment for adults and pediatric patients two years and older with SAA in combination with standard immunosuppressive therapy (IST).

FDA approves Novartis drug Promacta for first-line SAA